Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Potential Central Glucoregulatory Compounds to Treat/ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers

Next Previous
Search
Trial Profile

Evaluation of Potential Central Glucoregulatory Compounds to Treat/ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary) ; Insulin (Primary) ; URB 597 (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics; Proof of concept
  • Acronyms EICAS

Most Recent Events

  • 21 Mar 2025 Status changed from not yet recruiting to withdrawn prior to enrolment. ( Lack of funding )
  • 12 Aug 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
  • 12 Aug 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top